西班牙国家髋部骨折登记处评估出院后抗骨质疏松治疗处方患者特征
本研究基于西班牙国家髋部骨折登记处(RNFC)2017年数据,纳入54家医院6701例脆性髋部骨折出院患者,分析出院时抗骨质疏松处方情况。结果显示处方率为36.5%(95%CI 35.8-37.2%),医院间差异大(0-94%),处方更常见于年轻、居家、既往治疗、功能认知状态较好、麻醉风险低及高容量医院患者。
要点
- 出院抗骨质疏松处方率36.5%,医院间范围0-94%,差异显著。
- 处方更常见于认知功能好、基线功能状态佳、麻醉风险低的患者。
- 高容量医院出院患者更可能获得处方,但高低处方率医院的患者总体特征相似。
核心结论
- 髋部骨折后抗骨质疏松处方在医院间存在广泛差异。
- 处方更可能起始于临床、功能和心理状态较好的患者以及高容量医院出院患者。
研究设计与样本
- 基于西班牙国家髋部骨折登记处(RNFC)2017年出院的脆性髋部骨折患者。
- 纳入54家医院共6701例患者,分析人口学、认知功能状态、伤前骨质疏松治疗、骨折类型、麻醉风险、医院容量及出院抗骨质疏松处方。
- 考虑患者按医院聚类,计算组内相关系数并拟合广义估计方程。
主要发现
- 出院抗骨质疏松处方率为36.5%(95%CI 35.8-37.2%),医院间范围0-94%。
- 因患者在医院内聚类的组内相关系数为47.9%。
- 处方更常见于较年轻、居家、既往接受骨质疏松治疗、基线功能和认知状态较好、麻醉风险较低及高容量医院出院的患者,均p<0.001。
- 高处方率与低处方率医院出院患者的总体特征相似。
临床怎么用
- 国家髋部骨折登记处可用于评估出院抗骨质疏松处方实践及医院间差异。
- 结果提示需关注处方选择偏倚,并引发对谁应接受及多少人应接受二级预防的思考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: This study was carried out to describe the profile of prescription of antiosteoporotic treatment at discharge after a hip fracture in the Spanish National Hip Fracture Registry. Prescription rates among hospitals ranged from 0 to 94% of patients discharged. The prescription rate was higher among patients with better cognitive and functional baseline status. PURPOSE: National hip fracture registries are useful for assessing current care processes. The goals of this study were as follows: first, to know the rate of antiosteoporotic prescription at discharge among hip fracture patients in hospitals participating in the Spanish National Hip Fracture Registry (RNFC); second, to compare the differences between treated and non-treated patients; third, to analyze patients' characteristics associated with antiosteoporotic prescription at discharge; and fourth, to evaluate whether there were differences in the profile of patients discharged from hospitals with high and low prescription rates. METHOD: Patients discharged after a fragility hip fracture in 2017 and participating in the RNFC were included. Demographic variables, cognitive and functional status, prefracture osteoporosis treatment, fracture type, anesthetic risk, hospital volume, and antiosteoporotic prescription at discharge were analyzed. Given that patients were clustered within hospitals, intraclass correlation was calculated and generalized estimating equations were fitted. RESULTS: A total of 6701 patients from 54 hospitals were included. Antiosteoporotic prescription at discharge was prescribed to 36.5% (CI95% 35.8-37.2%), with a wide inter-hospital variability (range 0-94%). The intraclass correlation due of clustering of patients within hospitals was 47.9%. Antiosteoporotic prescription was more likely in patients who were younger, lived at home, previously treated for osteoporosis, had better baseline functional and cognitive status, lower anesthetic risk, and were discharged from high-volume hospitals, all with p < 0.001. The general profile of patients discharged from hospitals with high and low rate of prescription was similar. CONCLUSIONS: There is a wide variability between hospitals regarding antiosteoporotic prescription after hip fracture. This is more likely to be initiated in patients with better clinical, functional, and mental status and in those discharged from hospitals with larger volumes of patients. These results offer insights regarding the selection of patients receiving secondary prevention and raises questions on who and how many should be treated.
引用
- Alarcon T, Ojeda-Thies C, Sáez-López P, et al. Usefulness of a national hip fracture registry to evaluate the profile of patients in whom antiosteoporotic treatment is prescribed following hospital discharge. Osteoporos Int. 2020. PMID: 32080755. doi:10.1007/s00198-020-05341-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。